跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
QINLOCK - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
QINLOCK
Authorized
STANDARD
QINLOCK
deciphera pharmaceuticals. llc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ef094fe801a03b4c
Company
deciphera pharmaceuticals. llc
Type
Standard
Approval Details
Approval Id
ef094fe801a03b4c
Drug Approval Canada Name
QINLOCK
Product Name
QINLOCK
Status
Marketed
Status Date
2020-12-10
Original Market Date
2020-12-10
Din
02500833
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01EX19 RIPRETINIB
Atc Name
l 01 ex 19
Aig Number
0162315001
Company Name
deciphera pharmaceuticals. llc
Company Address
200 Smith Street, Waltham, Massachusetts, United States, 02451
Active Ingredients
RIPRETINIB
50 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ef094fe801a03b4c
Type
Standard
Back to Health Canada Approvals